Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report